General Atlantic, L.P.
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), General Atlantic, L.P. reported 15 stock positions worth $3.0 billion. Its top holding was Alignment Healthcare (ALHC) at 38.1% of the portfolio, followed by Dlocal (DLO, 17.9%) and XP Class A (XP, 13.7%). Compared with Q4 2024, it sold out of 1. The biggest sale was an exit from Third Harmonic Bio (THRD).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001017645
- Portfolio Value
- $3.0B (Q1 2025)
- SEC Filing
- 0000950142-25-001365 ↗ filed May 14, 2025
Holdings Value
Holdings 15 stocks · $3.0B
| ALHC Alignment Healthcare Inc. | 38.12% | 60,993,323 | $1.1B | No change |
| DLO Dlocal Ltd. | 17.89% | 63,906,695 | $533.0M | No change |
| XP XP Inc. Class A | 13.67% | 29,617,733 | $407.2M | No change |
| ALKT Alkami Technology Inc. | 8.50% | 9,645,318 | $253.2M | No change |
| AKRO Akero Therapeutics Inc. | 7.11% | 5,233,989 | $211.9M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 4.67% | 9,681,818 | $139.2M | No change |
| PHVS Pharvaris NV | 3.97% | 7,531,252 | $118.2M | No change |
| EWCZ European Wax Center Inc. Class A | 1.74% | 13,110,492 | $51.8M | No change |
| RPRX Royalty Pharma PLC Class A | 1.57% | 1,500,000 | $46.7M | No change |
| IMCR Immunocore Holdings PLC-ADR | 1.26% | 1,261,684 | $37.4M | No change |
| RSKD Riskified Ltd. Class A | 0.83% | 5,324,998 | $24.6M | No change |
| SLRN Acelyrin Inc. | 0.22% | 2,695,327 | $6.7M | No change |
| ADAG Adagene Inc.-ADR | 0.20% | 3,825,952 | $5.8M | No change |
| CONTEXTLOGIC INC - A | 0.14% | 609,616 | $4.3M | No change |
| GROV Grove Collaborative Holdings | 0.11% | 2,474,859 | $3.3M | No change |
Portfolio Sells Q4 2024 → Q1 2025
| THRD Third Harmonic Bio Inc. | Sold out | 0.00% | −1.24 |
Portfolio Buys Q4 2024 → Q1 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $2.9B | LFTO, DLO, CHYM, ALKT, XP |
| Q1 2026 | 12 | $2.1B | DLO, CHYM, XP, ALKT, PHVS |
| Q4 2025 | 13 | $2.9B | DLO, CHYM, XP, ALKT, ALHC |
| Q3 2025 | 16 | $3.3B | DLO, XP, ALHC, CHYM, ALKT |
| Q2 2025 | 15 | $3.6B | DLO, CHYM, ALHC, XP, AKRO |
| Q1 2025 | 15 | $3.0B | ALHC, DLO, XP, ALKT, AKRO |
| Q4 2024 | 16 | $2.8B | DLO, ALHC, ALKT, XP, CNTA |
| Q3 2024 | 18 | $3.5B | ALHC, XP, DLO, SQSP, ALKT |
| Q2 2024 | 19 | $3.2B | XP, DLO, ALKT, ALHC, SQSP |
| Q1 2024 | 22 | $4.3B | DLO, XP, ALKT, HRT, SQSP |